Mereo BioPharma Group plc
MREO
$0.24
-$0.01-4.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.95% | -44.73% | -34.97% | -2.55% | -30.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.60% | -21.29% | -48.18% | 7.89% | -17.61% |
| Operating Income | 29.15% | 21.29% | 48.18% | -7.89% | 21.62% |
| Income Before Tax | 52.07% | 47.86% | -4.33% | 53.18% | -19.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.07% | 47.86% | -4.33% | 53.18% | -19.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.07% | 47.86% | -4.33% | 53.18% | -19.27% |
| EBIT | 29.15% | 21.29% | 48.18% | -7.89% | 21.62% |
| EBITDA | 29.67% | 21.82% | 50.81% | -9.13% | 22.10% |
| EPS Basic | 52.30% | 49.03% | -0.88% | 54.93% | -6.16% |
| Normalized Basic EPS | 52.36% | 48.93% | -1.06% | 55.01% | -6.13% |
| EPS Diluted | 52.30% | 49.03% | -0.88% | 54.93% | -6.16% |
| Normalized Diluted EPS | 52.36% | 48.93% | -1.06% | 55.01% | -6.13% |
| Average Basic Shares Outstanding | 0.52% | 2.23% | 3.27% | 3.87% | 12.32% |
| Average Diluted Shares Outstanding | 0.52% | 2.23% | 3.27% | 3.87% | 12.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |